Amarantus.png
Elto Pharma Receives Notice of Allowance in Canada for Patent Covering Use of Eltoprazine to Treat non-ADHD Cognitive Impairment
May 01, 2018 10:31 ET | Amarantus Bioscience Holdings, Inc.
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Elto Pharma, Inc., a specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc....